Bio-Gate AG
2.18
EUR
+0.02
(+0.93%)
ISIN
DE000BGAG0J3
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Marc Lloret-Grau
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nuremberg Germany
- Website
- bio-gate.de
- Similar Companies
- Business
- Bio-Gate AG is a Germany-based healthcare technology and biomaterials company that specializes in the development, manufacture, and commercialization of antimicrobial and antiviral surface coatings, material additives, and hygiene solutions. Founded in 2005 and headquartered in Nuremberg, Germany, the company operates primarily across four core segments: Medical Technology, Dermocosmetics, Wound Care, and Veterinary Medicine, while also serving industrial and consumer goods markets. Bio-Gate applies proprietary silver technologies to functionalize synthetic and metallic materials, preventing bacterial colonization, mitigating biofilm formation, and reducing infection risks across healthcare and daily life applications. The company offers a specialized portfolio of proprietary products, technologies, and technical services: HyProtect, an ultrathin, plasma-applied polysiloxane and pure metallic silver coating engineered for human and veterinary medical implants, trauma devices, orthopedic revision prostheses, dental implants, hernia meshes, and catheters; MicroSilver BG, a high-purity, microporous elemental silver additive featuring a sponge-like micro-particle structure for controlled ion release, supplied as an active ingredient for dermocosmetics, oral care formulations, chronic wound dressings, and orthopedic bone cements; Veterinary and Pet Care Products, comprising specialized dermatological sprays, gels, ear cleansers, and topical formulations utilizing MicroSilver BG to treat skin irritations and infections in companion animals and horses; Industrial and Consumer Solutions, consisting of antimicrobial masterbatches and additive compounds formulated for integration into plastics, polymers, coatings, varnishes, and functional textiles; and Testing and Development Services, providing contract research, customized material functionalization, surface analytics, and standardized antimicrobial testing through its accredited testing laboratory. Bio-Gate AG serves medical device manufacturers, pharmaceutical and cosmetic brands, veterinary distributors, healthcare institutions, and industrial component manufacturers across Europe, North America, and select international markets. The company conducts research, development, and laboratory services at its Nuremberg headquarters and operates specialized manufacturing and production facilities in Bremen, Germany. Bio-Gate conducts international commercialization through direct sales channels, strategic distribution agreements, and third-party representation, including North American representation via RFH BioTek Inc. The company operates QualityLabs BT GmbH, a wholly owned Nuremberg-based subsidiary specializing in microbiological testing and surface certification. In recent operational and corporate developments, Bio-Gate has advanced the multinational HIPrevision clinical study across clinical centers in Germany, Poland, and Spain to evaluate HyProtect-coated hip revision implants under European medical device regulations, aiming for commercial market introduction by 2028. The company has published positive clinical data demonstrating superior infection eradication in complex trauma applications, while accelerating the geographic expansion of its veterinary care portfolio across the United States, Canada, and Mexico. Operationally, Bio-Gate has completed production capacity expansions at its Bremen manufacturing plant and executed structural cost-optimization programs to enhance internal value creation and accelerate its trajectory toward operating profitability.